Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Wednesday the launch of its Nitazoxanide Tablets, 500 mg, the generic version of the reference listed drug Alinia.
Nitazoxanide is used to treat diarrhoea caused by certain parasites.
US annual sales for Nitazoxanide Tablets are approximately USD36.1m, based on the December 2024 moving annual total IQVIA data.
This launch expands ANI's portfolio and provides an alternative treatment option in the market.
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Veeda Group rebrands as 'Veeda Lifesciences'
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation